Understanding the ins and outs of lipoprotein (a) metabolism

被引:18
作者
Boffa, Michael B. [1 ,2 ]
Koschinsky, Marlys L. [1 ,3 ]
机构
[1] Univ Western Ontario, Schulich Sch Med & Dent, Robarts Res Inst, London, ON, Canada
[2] Univ Western Ontario, Schulich Sch Med & Dent, Dept Biochem, London, ON, Canada
[3] Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
apolipoprotein(a); catabolism; hepatocytes; lipoprotein(a); secretion; FAMILIAL HYPERCHOLESTEROLEMIA; TARGETING APOLIPOPROTEIN(A); ELEVATED LIPOPROTEIN(A); PCSK9; INHIBITION; BINDING-SITES; DOUBLE-BLIND; LP(A); GENE; ASSOCIATION; IDENTIFICATION;
D O I
10.1097/MOL.0000000000000823
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review This review summarizes our current understanding of the processes of apolipoprotein(a) secretion, assembly of the Lp(a) particle and removal of Lp(a) from the circulation. We also identify existing knowledge gaps that need to be addressed in future studies. Recent findings The Lp(a) particle is assembled in two steps: a noncovalent, lysine-dependent interaction of apo(a) with apoB-100 inside hepatocytes, followed by extracellular covalent association between these two molecules to form circulating apo(a). The production rate of Lp(a) is primarily responsible for the observed inverse correlation between apo(a) isoform size and Lp(a) levels, with a contribution of catabolism restricted to larger Lp(a) isoforms. Factors that affect apoB-100 secretion from hepatocytes also affect apo(a) secretion. The identification of key hepatic receptors involved in Lp(a) clearance in vivo remains unclear, with a role for the LDL receptor seemingly restricted to conditions wherein LDL concentrations are low, Lp(a) is highly elevated and LDL receptor number is maximally upregulated. The key role for production rate of Lp(a) [including secretion and assembly of the Lp(a) particle] rather than its catabolic rate suggests that the most fruitful therapies for Lp(a) reduction should focus on approaches that inhibit production of the particle rather than its removal from circulation.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 57 条
[1]   Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options [J].
Anagnostis, Panagiotis ;
Karras, Spyridon ;
Lambrinoudaki, Irene ;
Stevenson, John C. ;
Goulis, Dimitrios G. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (12) :967-977
[2]   Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia The ODYSSEY HoFH Trial [J].
Blom, Dirk J. ;
Harada-Shiba, Mariko ;
Rubba, Paolo ;
Gaudet, Daniel ;
Kastelein, John J. P. ;
Charng, Min-Ji ;
Pordy, Robert ;
Donahue, Stephen ;
Ali, Shazia ;
Dong, Yuping ;
Khilla, Nagwa ;
Banerjee, Poulabi ;
Baccara-Dinet, Marie ;
Rosenson, Robert S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (02) :131-142
[3]   Estrogen modulation of apolipoprotein(a) expression - Identification of a regulatory element [J].
Boffelli, D ;
Zajchowski, DA ;
Yang, ZY ;
Lawn, RM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (22) :15569-15574
[4]   Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein (a) Isoform Sizes and Background Cholesterol-Lowering Therapy [J].
Chan, Dick C. ;
Watts, Gerald F. ;
Coll, Blai ;
Wasserman, Scott M. ;
Marcovina, Santica M. ;
Barrett, P. Hugh R. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (07)
[5]   Lipoprotein metabolism in familial hypercholesterolemia [J].
Chemello, Kevin ;
Garcia-Nafria, Javier ;
Gallo, Antonio ;
Martin, Cesar ;
Lambert, Gilles ;
Blom, Dirk .
JOURNAL OF LIPID RESEARCH, 2021, 62
[6]   Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive of PCSK9 Inhibition With Alirocumab [J].
Chemello, Kevin ;
Beeske, Sandra ;
Thi Thu Trang Tran ;
Blanchard, Valentin ;
Villard, Elise F. ;
Poirier, Bruno ;
Le Bail, Jean-Christophe ;
Dargazanli, Gihad ;
Ho-Van-Guimbal, Sophie ;
Boulay, Denis ;
Bergis, Olivier ;
Pruniaux, Marie-Pierre ;
Croyal, Mikael ;
Janiak, Philip ;
Guillot, Etienne ;
Lambert, Gilles .
JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (06) :549-557
[7]   FGF19 Signaling Cascade Suppresses APOA Gene Expression [J].
Chennamsetty, Indumathi ;
Claudel, Thierry ;
Kostner, Karam M. ;
Trauner, Michael ;
Kostner, Gert M. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (05) :1220-+
[8]   Farnesoid X receptor represses hepatic human APOA gene expression [J].
Chennamsetty, Indumathi ;
Claudel, Thierry ;
Kostner, Karam M. ;
Baghdasaryan, Anna ;
Kratky, Dagmar ;
Levak-Frank, Sanja ;
Frank, Sasa ;
Gonzalez, Frank J. ;
Trauner, Michael ;
Kostner, Gert M. .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (09) :3724-3734
[9]   VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly [J].
Croyal, Mikael ;
Blanchard, Valentin ;
Ouguerram, Khadija ;
Chetiveaux, Maud ;
Cabioch, Lea ;
Moyon, Thomas ;
Billon-Crossouard, Stephanie ;
Aguesse, Audrey ;
Bernardeau, Karine ;
Le May, Cedric ;
Flet, Laurent ;
Lambert, Gilles ;
Hadjadj, Samy ;
Cariou, Bertrand ;
Krempf, Michel ;
Nobecourt-Dupuy, Estelle .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (03) :819-829
[10]   PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate [J].
Croyal, Mikael ;
Thi-Thu-Trang Tran ;
Blanchard, Rose Helene ;
Le Bail, Jean-Christophe ;
Villard, Elise F. ;
Poirier, Bruno ;
Aguesse, Audrey ;
Billon-Crossouard, Stephanie ;
Ramin-Mangata, Stephane ;
Blanchard, Valentin ;
Nativel, Brice ;
Chemello, Kevin ;
Khantalin, Ilya ;
Thedrez, Aurelie ;
Janiak, Philip ;
Krempf, Michel ;
Boixel, Christophe ;
Lambert, Gilles ;
Guillot, Etienne .
CLINICAL SCIENCE, 2018, 132 (10) :1075-1083